Dimensional Fund Advisors LP purchased a new stake in Bausch Health Companies Inc (NYSE:BHC) during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 5,280,029 shares of the company’s stock, valued at approximately $135,538,000. Dimensional Fund Advisors LP owned 1.51% of Bausch Health Companies as of its most recent SEC filing.
Several other large investors have also recently added to or reduced their stakes in the company. Virtu Financial LLC bought a new position in shares of Bausch Health Companies in the third quarter valued at approximately $558,000. Great West Life Assurance Co. Can acquired a new stake in shares of Bausch Health Companies in the third quarter worth $8,737,000. Pictet Asset Management Ltd. acquired a new stake in shares of Bausch Health Companies in the third quarter worth $2,881,000. D.A. Davidson & CO. acquired a new stake in shares of Bausch Health Companies in the third quarter worth $419,000. Finally, Chou Associates Management Inc. acquired a new stake in shares of Bausch Health Companies in the third quarter worth $42,330,000. 50.09% of the stock is currently owned by institutional investors.
In other Bausch Health Companies news, Director Schutter Richard U. De purchased 125,000 shares of the firm’s stock in a transaction on Thursday, September 13th. The shares were purchased at an average price of $23.96 per share, for a total transaction of $2,995,000.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Christina Ackermann sold 19,946 shares of Bausch Health Companies stock in a transaction on Tuesday, October 16th. The stock was sold at an average price of $24.98, for a total transaction of $498,251.08. The disclosure for this sale can be found here. Insiders have acquired 165,000 shares of company stock worth $3,890,700 in the last quarter. Corporate insiders own 11.54% of the company’s stock.
BHC opened at $24.47 on Thursday. Bausch Health Companies Inc has a fifty-two week low of $14.44 and a fifty-two week high of $28.45. The company has a debt-to-equity ratio of 7.55, a quick ratio of 0.91 and a current ratio of 1.14. The firm has a market cap of $8.56 billion, a price-to-earnings ratio of 6.39, a price-to-earnings-growth ratio of 0.32 and a beta of -0.28.
Bausch Health Companies (NYSE:BHC) last posted its quarterly earnings results on Tuesday, November 6th. The company reported $1.15 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.84 by $0.31. Bausch Health Companies had a negative net margin of 40.41% and a positive return on equity of 32.19%. The firm had revenue of $2.14 billion for the quarter, compared to the consensus estimate of $2.09 billion. The business’s quarterly revenue was down 3.7% compared to the same quarter last year. On average, sell-side analysts anticipate that Bausch Health Companies Inc will post 3.81 EPS for the current fiscal year.
BHC has been the topic of several research analyst reports. ValuEngine downgraded shares of Bausch Health Companies from a “hold” rating to a “sell” rating in a research note on Friday, September 7th. Royal Bank of Canada set a $30.00 price objective on shares of Bausch Health Companies and gave the stock a “hold” rating in a research note on Monday, October 8th. Cantor Fitzgerald restated a “buy” rating and issued a $32.00 price objective on shares of Bausch Health Companies in a research note on Wednesday, September 12th. JPMorgan Chase & Co. raised their price objective on shares of Bausch Health Companies to $18.00 and gave the stock an “underweight” rating in a research note on Wednesday, August 8th. Finally, HC Wainwright restated a “hold” rating and issued a $20.00 price objective on shares of Bausch Health Companies in a research note on Friday, August 31st. Three research analysts have rated the stock with a sell rating, six have issued a hold rating and four have given a buy rating to the company. The company presently has an average rating of “Hold” and a consensus target price of $28.18.
WARNING: “Dimensional Fund Advisors LP Purchases New Stake in Bausch Health Companies Inc (BHC)” was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece on another website, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece can be read at https://www.dispatchtribunal.com/2018/12/06/dimensional-fund-advisors-lp-purchases-new-stake-in-bausch-health-companies-inc-bhc.html.
Bausch Health Companies Company Profile
Bausch Health Companies Inc develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. It offers dermatology products that treat a range of conditions, including actinic keratosis, acne, atopic dermatitis, psoriasis, cold sores, athlete's foot, nail fungus, and other dermatoses, as well as provides aesthetic medical devices, which address various conditions, including facial wrinkles, acne, pigmentation conditions, body sculpting, skin tightening, and laser hair removal.
Recommended Story: Consumer Price Index (CPI)
Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with MarketBeat.com's FREE daily email newsletter.